A Study of Vinflunine in Patients With Gastric Cancer

Inclusion Criteria: * Patients with locally advanced or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction who have progressed on a fluoropyrimidine or taxane-containing regimen in any combination in one prior first line treatment. * EGOC performance status of 0,1 or 2 * Men and women, 18 years of age and older Exclusion Criteria: * Patients having received more than one previous systemic chemotherapy regimen in any setting. * Major abdominal surgery within 2 months or any other surgery under general anesthesia within 4 weeks * Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic intestinal disease (e.g. ulcerative colitis) * Prior radiation to \>=30% of the bone marrow and/or radiation within 4 weeks prior to enrollment * Acute or chronic hepatitis * Known HIV infection * A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms * A history of additional risk factors for Torsade de Pointes (e.g., heart failure hypokalemia, family history of Long QT Syndrome)